TLDR The study concluded that yellow dots are a common and useful sign for diagnosing alopecia areata in dark-skinned individuals and may indicate the severity of the condition.
The study examined dermoscopic features of alopecia areata (AA) in 116 dark-skinned Indian individuals, finding that these features were consistent with those reported in Western literature. Yellow dots (YDs) were particularly sensitive for diagnosing AA, appearing more frequently in Indian prepubertal patients than in Western counterparts. The study also found a higher number of YDs per field of vision (YD/FOV) in more severe cases of AA, although other dermoscopic features did not correlate with disease severity. The research suggested that the prevalence of YDs and the influence of local hair care practices, like oiling, could affect dermoscopic observations. The study proposed using YD/FOV as a potential measure for grading AA severity.
Cited in this study
6 / 6 results
12 citations
,
January 2014 in “Menoufia Medical Journal” Dermoscopy improves diagnosis of hair and scalp disorders and can help avoid unnecessary biopsies.
245 citations
,
November 2012 in “Journal of The American Academy of Dermatology” Dermatoscopy is useful for identifying different hair and scalp conditions and can reduce the need for biopsies.
76 citations
,
January 2011 in “Indian Journal of Dermatology/Indian journal of dermatology” Dermoscopy is a useful tool for diagnosing and managing alopecia areata.
56 citations
,
June 2010 in “Clinical and experimental dermatology” Coudability hairs are useful markers for alopecia areata activity.
25 citations
,
December 2008 in “Journal of Dermatological Case Reports” Skin color may change how alopecia areata looks under a dermoscope.
196 citations
,
June 2008 in “International Journal of Dermatology” Dermoscopy helps diagnose and manage alopecia areata by showing specific hair changes.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
